NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-102-2020-0-JP-07 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY JP National Stage 2022-556460 Pending
NCI E-061-2020-0-JP-07 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY JP National Stage 2022-556459 Pending
NCI E-176-2014-0-KR-66 Anti-Human Papillomavirus 16 E7 T Cell Receptors KR DIV 2022-7032043 Issued
NCI E-088-2020-0-IN-08 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION IN National Stage 202247052620 Pending
NCI E-210-2018-1-PCT-02 Chimeric adaptor and kinase signaling proteins and their use in immunotherapy PCT PCT PCT/US2022/076358 Expired
NCI E-074-2020-1-EP-06 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION EP National Stage 21710740.8 Pending
NCI E-074-2020-1-KR-09 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION KR National Stage 2022-7031589 Pending
NCI E-102-2020-0-CA-04 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY CA National Stage 3171583 Pending
NCI E-061-2020-0-CA-04 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY CA National Stage 3171559 Pending
NCI E-239-2017-0-US-20 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS US DIV 17/931,391 Pending
NCI E-075-2020-0-CA-04 SYSTEMS, METHODS, AND DEVICES FOR EX VIVO ANALYSIS OF RESECTED TISSUE SAMPLES CA National Stage 3171412 Pending
NIAID E-297-2016-2-JP-10 VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES JP DIV 2022-144109 Issued
NCATS E-172-2021-0-PCT-02 SYNTHETIC HUMANIZED LLAMA NANOBODY LIBRARY AND USE THEREOF TO IDENTIFY SARS-COV-2 NEUTRALIZING ANTIBODIES PCT PCT PCT/US2022/076221 Expired
NEI E-194-2021-0-PCT-02 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging PCT PCT PCT/US2022/076135 Expired
NIAID E-185-2022-0-US-01 Engineered SARS-CoV-2 Antibodies With Increased Neutralization Breadth US 63/404,473 Expired
NCI E-074-2020-1-IN-07 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION IN National Stage 202247050807 Pending
NIDDK E-043-2020-0-CA-01 RNA Target Enrichment or Depletion of Biological Samples CA National Stage 3174707 Pending
NIDDK E-101-2020-0-US-04 Antibacterial And Antifungal Polyketides From Environmental Amycolatopsis Spp. US National Stage 17/909,051 Pending
NIAID E-052-2021-0-CA-01 Engineered Influenza Neuraminidase Antigens CA National Stage 3170375 Pending
NCI E-169-2022-0-US-01 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes US 63/374,307 Expired
NIAID E-183-2022-0-US-01 Multi Protein Nanoparticle Monkeypox Vaccine US 63/402,702 Expired
CC E-180-2022-0-US-01 SYSTEMS OF METHODS FOR DETECTING OMICRON SARS-CoV-2 VARIANTS WITH DEEP LEARNING AND VOICE DATA INPUT US 63/374,214 Expired
NCI E-234-2014-1-AU-02 METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF AU DIV 2022224780 Pending
NCI E-105-2019-0-CN-05 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION CN National Stage 202080096478.2 Pending
NCI E-169-2021-0-PCT-02 MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE PCT PCT PCT/US2022/075678 Expired
NCI E-088-2020-0-US-13 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION US National Stage 17/802,464 Pending
NCI E-168-2011-0-US-47 METHODS AND COMPOSITIONS FOR INHIBITING POLYOMAVIRUS-ASSOCIATED PATHOLOGY US DIV 17/822,345 Abandoned
NCI E-088-2020-0-CN-06 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION CN National Stage 202180016761.4 Pending
NCI E-088-2020-0-JP-09 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION JP National Stage 2022-551537 Pending
NEI E-004-2017-0-US-08 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY US DIV 17/894,773 Pending
NHLBI E-090-2020-0-US-03 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND
METHODS OF USE 		US CON 17/821,703 Abandoned
NCI E-088-2020-0-AU-04 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION AU National Stage 2021225872 Pending
NIAID E-240-2023-0-US-02 VACCINES AGAINST CORONAVIRUSES US 63/400,334 Expired
NCI E-088-2020-0-CA-05 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION CA National Stage 3169086 Pending
NIAID E-086-2020-0-IN-09 SARS-CoV-2 VACCINE IN National Stage 202217047972 Pending
NCI E-088-2020-0-NZ-16 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION NZ National Stage 791348 Pending
NCI E-088-2020-0-GB-12 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION GB National Stage 2212195.8 Pending
NCI E-088-2020-0-BR-14 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION BR National Stage BR112022016661-3 Pending
NIAID E-240-2023-0-US-01 VACCINES AGAINST CORONAVIRUSES US 63/399,990 Expired
NIAID E-152-2022-0-US-01 HIV-1 IMMUNOGENS AND THEIR USE US 63/399,709 Expired
NIAID E-168-2020-2-CA-01 Corona Virus Binders CA National Stage 3166967 Abandoned
NCI E-088-2020-0-SG-11 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION SG National Stage 11202252357K Pending
NCI E-042-2014-0-IN-35 Chimeric Antigen Receptors Targeting CD-19 IN DIV 202248047256 Pending
NIAID E-020-2020-0-US-04 EPSTEIN-BARR VIRUS MONOCLONAL ANTIBODIES AND USES THEREOF US National Stage 17/800,706 Pending
NCI E-116-2017-0-US-04 Compositions and Methods for Treating Cancer with Anti-CD33 Immunotherapy US CON 17/820,724 Pending
NEI E-057-2020-0-US-06 Method and Systems for Predicting Rates of Progression of Age-Related Macular Degeneration US National Stage 17/904,573 Pending
NCI E-159-2019-0-EP-05 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) EP National Stage 21705769.4 Pending
NCATS E-168-2019-0-JP-06 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN
PLURIPOTENT STEM CELLS 		JP National Stage 2022-549610 Pending
NCI E-088-2020-0-MX-15 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION MX National Stage MX/a/2022/010157 Pending
NCI E-159-2019-0-AU-04 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) AU National Stage 2021210915 Pending